AOD9604 is a research-grade peptide derived from the C-terminal fragment (176–191) of human growth hormone (hGH). This modified sequence retains the lipolytic properties of its parent region while eliminating growth-promoting activity, making it a targeted tool for studying fat-cell metabolism and energy regulation in controlled laboratory environments.
In preclinical research, AOD9604 has been shown to modulate lipolysis and inhibit lipogenesis without activating the IGF-1 receptor. This selectivity makes it valuable for exploring metabolic pathways, adipocyte signaling, and lipid turnover models.
Produced in the United States under strict quality standards, each batch undergoes third-party analytical testing to verify identity, purity, and structural integrity. Intended strictly for in vitro research and not for human use.
Primary Research Areas:
- Lipolysis pathway activation and adipocyte fat-metabolism studies
- Regulation of lipogenesis and downstream metabolic signaling
- Growth-hormone fragment biology and receptor-independent mechanisms
- Energy-balance modulation and mitochondrial metabolic pathways
- Adipocyte size, lipid turnover, and fat-storage regulation in preclinical models
- Biochemical mapping of peptide–lipid interactions and metabolic homeostasis
AOD 9604 Structure:
Molecular Formula: C78H123N23O23S2
Molecular Weight: 1815.12 g/mol
PubChem ID: 71300630
CAS Number: 42464-96-0
Synonyms: AOD-9604, Tyr-hGH Fragment 176-191, HGH Fragment 177-191, Lipotropin
